D.D. MUKHAMETOVA¹, E.S. BODRYAGINA¹, A.KH. ODINTSOVA², L.M. KUPKENOVA¹, D.F. SHAFIKOVA¹, B.M. FONTENELLE¹, D.I. ABDULGANIEVA^1, 2

 ¹Kazan State Medical University, Kazan

2Republic Clinical Hospital, Kazan

  Contact details:

Mukhametova D.D. — PhD (medicine), Assistant Lecturer of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7 (843) 237-32-61, e-mail: muhdilyara@gmail.com

The article presents a clinical case of a new coronavirus infection in a patient with CD. The onset of the viral infection occurred during severe exacerbation of CD, what led to induction of infliximab therapy. The difficulty of managing patients with COVID-19 and immunoinflammatory diseases is discussed.

Key words: Crohn’s disease, COVID-19, infliximab.

REFERENCES

1. Aysha H.A., Ralley E.P., Clarissa A.R. et al. Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient. Aliment Pharmacol Ther, 2020, Jul, vol. 52 (1), pp. 54–72. DOI: 10.1111/apt.15779
2. Wu Y., Guo C., Tang L. et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol, 2020, May, vol. 5 (5), pp. 434–435. DOI: 10.1016/S2468-1253(20)30083-2
3. Wetwittayakhlang P., Albader F., Golovics P.A., Hahn G.D., Bessissow T., Bitton A., Afif W., Wild G., Lakatos P.L. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol, 2021, Nov 30, vol. 2021. 7591141. DOI: 10.1155/2021/7591141
4. Clinical reference to diagnostics and the knowledge of the crown and foreign (Project). Koloproktologiya, 2020, no. 19 (2), pp. 8–38 (in Russ.). DOI: 10.33878/2073-7556-2020-19-2-8-38
5. Abdullah A., Neurath M.F., Atreya R. Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes? Visc Med, 2020, vol. 36, pp. 338–342. DOI: 10.1159/000508740
6. Sperger J., Shah K.S., Lu M., Zhang X., Ungaro R.C., Brenner E.J., Agrawal M., Colombel J.F., Kappelman M.D., Kosorok M.R. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open, 2021, Nov 12, vol. 11 (11), p. e049740. DOI: 10.1136/bmjopen-2021-049740
7. Abdullah A., Neurath M.F., Atreya R. Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes? Visc Med, 2020, Aug, vol. 36 (4), pp. 338–342. DOI: 10.1159/000508740
8. Segal J.P., Moss A.C. Implications of recurrent SARS-CoV-2 outbreaks for IBD management. Frontline Gastroenterol, 2020, Jun 24, vol. 12 (4), pp. 316–321. DOI: 10.1136/flgastro-2020-101531
9. Guo H., Tang J., Huang Z., Li B., Yang Q., Chao K., Gao X. P532 Delay of maintenance infliximab increases the risk of relapse in Crohn’s disease during the COVID-19 pandemic. J Crohns Colitis, 2021, May 27, vol. 15 (Suppl 1), p. S507. DOI: 10.1093/ecco-jcc/jjab076.654
10. Melong Pianta Taleng C.M., Lauper K., Gilbert B., Cunningham T., Guemara R., Brulhart L., Dan D., Courvoisier D., Finckh A. Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab. RMD Open, 2021, Dec, vol. 7 (3), p. e001711. DOI: 10.1136/rmdopen-2021-001711
11. Alhalabi M., Eddin K.A., Ali F., Abbas A. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. Medicine (Baltimore), 2022, Jan 28, vol. 101 (4), p. e28722. DOI: 10.1097/MD.0000000000028722